A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
This randomized phase III trial studies rituximab after stem cell transplant and to see how
well it works compared with rituximab alone in treating patients with in minimal residual
disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies,
such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving
chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body
and helps make room in the patient''s bone marrow for new blood-forming cells (stem cells) to
grow. After treatment, stem cells are collected from the patient''s blood and stored. More
chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem
cells are then returned to the patient to replace the blood-forming cells that were destroyed
by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in
treating patients with mantle cell lymphoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.